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Abstract 
Background: Lifestyle and dietary advice typically precedes or accompanies the prescription 
of statin medications. However, evidence for adherence to this advice is sparse. The objective 
was to compare saturated fat intake, exercise, alcohol consumption and smoking between 
statin users and non-users in Australia. 
Methods: Data were analyzed for 4,614 participants aged ≥37 years in the Australian 
Diabetes, Obesity and Lifestyle study in 2011-2012. Statin use, smoking status and physical 
activity were self-reported. Saturated fat and alcohol intake were measured via a food 
frequency questionnaire. Multinomial Logistic regression was used to compute adjusted odds 
ratios (ORs) and 95% confidence intervals (CIs) for the associations between statin use and 
the four lifestyle factors. All models were adjusted for age, sex, education, number of GP 
visits, body mass index, hypertension, diabetes and prior cardiovascular diseases. 
Results: In total 1108 (24%) participants used a statin. Statin users were 29% less likely to be 
within the highest quartile vs. the lowest quartile of daily saturated fat intake compared to 
non-users (OR 0.71, 95%CI 0.54-0.94). There were no statistically significant associations 
between statin use and smoking, physical activity or alcohol consumption. 
Conclusions: Smoking status, alcohol consumption and exercise level did not differ between 
users and non-users of statins. However, statin users were less likely to consume high levels 
of saturated fat than non-users. We found no evidence that people took stains to compensate 
for a poor diet or lifestyle. 
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Introduction 
Lifestyle and dietary modifications are the cornerstone of primary and secondary prevention 
of cardiovascular disease (CVD). Smoking cessation, low-moderate alcohol consumption, 
exercise and reduction in saturated fat intake reduce CVD risk.1-4 Guidelines recommend that 
lifestyle and dietary advice should precede or accompany the prescription of statin 
medications.5, 6 However, as lifestyle and dietary modifications can be challenging to 
implement and maintain, guidelines may not be followed.7, 8 
Meta-analyses have demonstrated the effectiveness of statin treatment in reducing 
cardiovascular-related mortality and morbidity.9, 10 The prescribing of statins has increased 
rapidly in Australia, Europe and the US. The prevalence of statin use increased from 17% in 
2001 to 35% in 2012 among Australian veterans.11 In the UK, the threshold for prescribing 
statins for primary prevention has been lowered from a 20% 10-year CVD risk to 10% 10-
year CVD risk.12 New US guidelines suggest statins be prescribed to those with a 7.5% 10-
year risk.13 This corresponds to an estimated additional 13 million individuals being eligible 
for statin therapy.13  
It is not known whether statin use complements or substitutes a healthy lifestyle and diet. 
Patients may perceive that statins represent an alternative path to health benefits,7 and 
prescribing of statins may diminish clinicians’ focus on CVD risk reduction via lifestyle and 
diet.14 Previous studies comparing lifestyle factors between statin users and non-users have 
reported inconsistent findings. A Swedish study in 2012 reported statin users were more 
likely to understand the importance of CVD risk reduction and were more likely to undertake 
lifestyle modifications.15 However, more recent US studies have reported that statin users had 
lower exercise levels16, and greater increases in caloric and fat intake than non-users of 
statins.17 These findings may be explained by risk compensation, in which people receiving a 
particular risk-lowering intervention are more likely to engage in risky behaviors.18 
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Alternatively, statins may cause muscular pain that discourages exercise or be prescribed to 
patients with comorbidities that prevent participation in exercise.16, 19  
No population-based studies on the association between statin use and lifestyle or diet have 
been conducted in Australia. The objective of this study was to compare saturated fat intake, 
exercise, alcohol consumption and smoking between statin users and non-users in Australia.  
 
Methods 
Study design, setting and participants 
The Australian Diabetes, Obesity and Lifestyle Study (AusDiab) is a 12-year longitudinal 
population based study. The baseline assessment was conducted 1999-2000, during which a 
total of 11,247 people aged 25 years and older in 42 randomly selected urban and rural areas 
across seven states and territories consented to participate. Data on clinical, demographic, 
health and lifestyle factors were collected using a series of interviewer and self-administered 
questionnaires with biomedical examinations conducted at local testing sites. Two follow-up 
examinations were conducted. The first follow-up took place in 2004-2005 (wave 2) and 
6,400 (59.3%) of eligible participants from baseline participated. The second follow-up took 
place in 2011-2012 (wave 3) and 4,614 (44.6%) of eligible participants from the baseline 
assessment participated. The full study methods and response rate for the baseline survey 
have been described previously.20 The current study was a cross sectional analysis of data 
collected in 2011-2012 (wave 3). 
 
Definitions and Measurements 
Medication use was self-reported by participants using a self-administered questionnaire. All 
medications were coded using the Anatomical Therapeutic Chemical (ATC) classification 
recommended by the World Health Organization (WHO).21 Statin users were defined as those 
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who took a statin (ATC codes C10AA, C10BA, C10BX) for at least 2 weeks within the last 3 
months. 
The lifestyle factors measured as outcomes were smoking status, alcohol consumption, 
exercise level and saturated fat intake. Smoking status was measured via self-administered 
questionnaire and participants were categorized as current smokers, former smokers or never 
smokers. Current smokers included those who smoked on a daily basis, former smokers 
included those who smoked less than daily in the past 3 months, and never smokers were 
defined who smoked less than 100 cigarettes during their lifetime. This categorization was 
consistent with previous research.20  
Physical activity was measured via a self-administered questionnaire using questions 
regarding time spent doing vigorous and moderate physical activity in the previous week. 
Physical activity was categorized consistent with previous research,20 into sedentary (no 
participation in physical activity in the previous week), insufficiently active (>0-149 minutes 
of moderate activity in the previous week and >0-74 minutes of vigorous activity in the 
previous week) and sufficiently active (≥150 minutes of moderate-intensity or ≥75 minutes of 
vigorous activity in the previous week). 
Saturated fat intake as grams per day was calculated using a self-administered food frequency 
questionnaire (FFQ), recalling intake over the previous 12 months.20 Saturated fat intake was 
expressed as a percentage of total daily energy intake and categorized into quartiles.22 
Daily alcohol consumption was obtained via the FFQ and expressed in grams of ethanol per 
day. Daily alcohol consumption was categorized into no drinking (0g), low-moderate 
drinking (>0 - 20g), heavy drinking (>20- 40g) and excessive drinking (>40g), where 10g of 
alcohol is equivalent to 1 unit of alcohol.4, 23 
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Covariates 
Age, sex, education level, number of general practitioner (GP) visits, body mass index (BMI), 
hypertension, diabetes and prior CVD were considered as covariates. Participant’s education 
level was assessed at baseline and wave 2. If a participant reported a higher level of education 
at wave 2 then this level was used to replace their baseline response. Participants were 
categorized into having not attended school, some primary or secondary education including 
completion of secondary education vs. having some education above secondary level. The 
number of GP visits within the last three months was obtained via an interviewer 
administered questionnaire. This variable was categorized into 0 visits, 1 visit, 2 visits and ≥3 
visits.  BMI (kg/m2) was calculated during biomedical examinations and was categorized into 
normal (BMI <25.0), overweight (BMI 25.0-29.9) and obese (BMI ≥30.0).24 Hypertension 
was defined based on blood pressure measurement and participant’s self-report of 
medications used for treating hypertension. Blood pressure (BP) measurements were 
completed in a seated position using an automated blood pressure monitor which was 
regularly calibrated (Dinamap® Pro-series Monitor Model DP 101– NIBP, Pulse and 
recorder, GE Medical Systems Information Technologies, Milwaukee, USA). Three 
measurements were taken at 30 second intervals. The mean of the first two measurements 
were taken unless the difference between the first and second measurement was greater than 
10 mmHg. In this case the third measurement was considered, and the mean of the two 
closest readings was used. Hypertension was categorized as normotension (BP <140/90 
mmHg and no medication use for hypertension), untreated hypertension (BP ≥140/90 mmHg 
and no medication use for hypertension) and treated hypertension (those who reported taking 
medications for hypertension).25 
Participants were considered to have diabetes if their fasting blood glucose was ≥7.0 mmol/L, 
two-hour blood glucose was ≥11.1 mmol/L, or they reported using medications for diabetes 
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(ATC code A10).20, 26 Participants were regarded to have prior CVD if they self-reported 
having had angina, stroke or myocardial infarction (MI) at baseline, had a MI, stroke, 
coronary artery angioplasty surgery or coronary artery bypass surgery between baseline and 
wave 3, or reported using nitrates (ATC code C10DA) at wave 3. 
 
Statistical Analysis  
Demographic and clinical characteristics of statin users and non-users were presented as 
proportions or means with standard deviations. The association between statin use and each 
lifestyle factor was examined using multinomial logistic regression. One regression model 
was computed for each of the four lifestyle factors. For each model, statin use (yes/no) was 
the primary exposure variable and age, sex, hypertension, diabetes, BMI, number of GP visits 
in the previous 3 months, prior CVD and lifestyle factors other than the outcome were treated 
as covariates. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. The 
analyses were performed using SAS (version 9.4, Cary, NC). 
To investigate the representativeness of participants at wave 3 of the original cohort at 
baseline we compared baseline characteristics between those participants who attended and 
those who did not attend the wave 3 examination. The proportion on females was similar 
between the groups, but participants who attended wave 3 were younger (mean age 48.9 
years vs. 53.7 years). Attendees had on average less GP visits during the previous 12 months, 
the proportion of people with hypertension, diabetes and prior cardiovascular disease were 
lower and they had lower baseline prevalence of lipid lowering medicine use than those who 
did not attend.  
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Results 
A total of 1108 of the 4614 participants (24%) in wave 3 used a statin. The mean age of statin 
users was 67.8 years compared to 58.6 years in non-users. Half of all statin users were male 
(51.3%) compared to only 42.6% of non-users. The prevalence of prior CVD, diabetes and 
treated hypertension was higher among statin users compared to non-users (corresponding 
comparisons of 21.7% vs 2.7%, 25.2% vs. 5.1% and 57.2 vs. 21.3% respectively). The 
characteristics of statin users and non-users are summarized in Table 1. The prevalence of 
current smoking was lower in statin users than non-users (3.8% in statin users, 6.3% in non-
users).  
After adjustment for the covariates, statin use was not associated with being in the second 
(OR=1.05; 95% CI=0.82-1.35) or third (OR=0.80; 95% CI=0.62-1.04) quartile vs. the lowest 
quartile of daily saturated fat intake (Table 2). However, statin users were 29% less likely to 
be within the highest quartile vs. the lowest quartile of daily saturated fat intake compared to 
non-users (OR=0.71, 95% CI=0.54-0.94). There was no statistically significant associations 
between statin use and smoking, physical activity or alcohol consumption. 
 
 
Discussion 
The main finding of this study was that statin users were 29% less likely consume high 
amounts of saturated fat as a percentage of total daily energy intake compared to non-users. 
Statin users and non-users were equally likely to consume high levels of alcohol and have 
sedentary lifestyle. Similarly, there was no difference in current smoking and former 
smoking, when adjusting for clinically relevant covariates. 
Our study found statin users had lower saturated fat intake compared to non-users. This is 
consistent with a previous study in Sweden which found statin users had better dietary habits 
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compared to non-users.15 Statin users may be more exposed to dietary information from their 
healthcare professionals. However, another US study showed that caloric and fat intake 
among statin users increased by 9.6% over a 10 year period among the US general population 
while in non-users the intake remained constant over the same period.17 This suggest that the 
attitudes towards dietary recommendations may change over time, where people prescribed 
statins increasingly accept statins as a compensatory measure for an unhealthy diet. It is 
unclear whether the lifestyle behaviors of statin users in the US are generalizable to Australia. 
Unlike the US repeated cross-sectional study, our study was single cross-sectional study and, 
therefore, we were unable to assess whether lifestyle factors changed over time. Further 
longitudinal research is needed to determine whether possible lifestyle modifications among 
statin users in Australia are sustained over time. 
Furthermore, the inconsistencies between Swedish, US and Australian research suggest that 
statin users in these countries may have a different lifestyle profile.15, 17 This is an important 
consideration for extrapolating the findings of research that has investigated the 
cardiovascular outcomes of statin users in these countries. 
In the present study, smoking status did not differ between statin users and non-users in the 
adjusted analyses with low rates of current smokers in both groups (3.8% and 6.3% 
respectively). The finding is consistent with previous literature where people have been 
observed to continue smoking despite known negative health effects.27 Barriers associated 
with smoking cessation range from reliance on smoking for stress management, not seeking 
adequate professional help,28 fear of weight gain and concerns regarding costs, particularly in 
vulnerable groups.27 Moreover, a significant proportion of non-smokers with CHD who are 
treated with statins are exposed to passive smoking, which may hinder smoking cessation.29, 
30 One study found that GP’s only initiated discussion regarding smoking cessation when 
patients presented with smoking related symptoms.33 Physicians perceived discussions were 
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too time consuming. Lack of support from physicians and lack of patients' awareness of 
cardiovascular risk factors may be a barrier to healthy lifestyle changes.31, 32  
Moreover, a review of several landmark trials observed that smoking diminishes the benefits 
of statins in reducing CVD risk.34 The review found that the risk of a CVD event in untreated 
non-smokers was of the same magnitude to the risk of smokers taking statins. Therefore, 
although the prevalence of current smoking in the present study was low, the importance of 
smoking cessation may need to be re-iterated to smokers who are prescribed statins.   
This study showed no association between statin use and physical activity. It is possible that 
statin users may have exercised less than non-users prior to statin initiation or that statin-users 
may have conditions which inhibit their ability to exercise. Once prescribed statins, people 
may have increased their exercise levels to the same level as non-users however further 
longitudinal research is needed. Previous studies have found  that statin users undertake less 
exercise than non-users.16 One possible explanation for these findings may be due to statin 
related side effects ranging from rare cases of rhabdomyolysis to more common muscle 
weakness and muscle pain.35 A study in France found among 7,924 patients taking statins, 
11% experienced muscle symptoms, 4% had symptoms severe enough to interfere with daily 
activities, and 0.4% were confined to bed with their symptoms.36 
No difference in alcohol consumption between statin users and non-users was found. There is 
no consensus on the effect of statin use on alcohol consumption as previous studies have 
produced conflicting results. A recent study reported that statin use was associated with a 
15% increase in moderate alcohol use among men,37 however other studies have observed 
lower alcohol consumption among statin users.38 Only 4% of GPs surveyed reported asking 
patients about their alcohol consumption ‘all of the time’39 which may reduce patient 
awareness about the effects of alcohol. Low-moderate alcohol consumption of up to two 
standard drinks daily has been shown to be the most beneficial in reducing CVD risk.40 
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Despite this, non-drinkers are not advised to start drinking to reduce their CVD risk.41 A 
meta-analysis of brief interventions in primary care aimed at reducing alcohol consumption 
demonstrated a decline of 38 g of ethanol per week following intervention.42 However, this 
intervention may be underutilized due to healthcare workers having insufficient time or lack 
of training39 which may have implications for excessive drinkers, who could potentially 
benefit from such service. 
The intensity of preventative actions recommended by clinicians may have been linked to 
participants’ total cardiovascular risk. It is possible that prescribers of statins were more 
proactive in managing a range of cardiovascular risk factors, including smoking, diet, 
lifestyle and diabetes. We are unable to determine what extent statin users and non-users may 
have received different advice from their clinicians, and to what extent this advice was 
followed by patients. Our study was cross-sectional in design and, therefore, it was not 
possible to determine whether statin users had poorer smoking, dietary and lifestyle behaviors 
prior to statin initiation. 
 
Strengths and limitations 
This study has several strengths. The data consisted of a random sample of more than 4600 
participants from urban suburban and regional areas across Australia. The data were collected 
in 2011-2012 and reflect relatively recent Australian prescribing and lifestyle patterns. To 
ensure a representative sample stratified cluster sampling was employed. Multivariate 
analyses were performed to accommodate potential confounding factors. 
There are some limitations to the present study. Self-reporting of statin use and lifestyle 
factors may have caused some participants to incorrectly report their statin use or lifestyle. 
This may have resulted in over- or under-estimation of the effect of statin use or the 
covariates. The participation rate at wave three was 4614 of the 11,247 who consented to 
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participate at baseline. Although we utilized the most recent data collected, participants at 
wave three might not be a representative sample of those at baseline. We compared the 
baseline characteristics of those who participated to those who did not participate at wave 
three. This shows that participants were less likely to be… Missing data in this analysis were 
excluded. Although the number of missing values per variable was relatively small (<12%), 
this might have led to partially biased estimates in our multivariate analyses. For example, if 
food frequency diary was not completed for those who were excessive alcohol consumers or 
had high saturated fat intake, this might have caused underestimation of these parameters. 
The cross-sectional design did not allow an assessment of causality related to statin use and 
lifestyle factors. This also means that we did not have information on statin initiation and 
how lifestyle factors may have changed over time.  
 
Conclusion 
Statin users had lower saturated fat intake than non-users. However, there was no difference 
in smoking status, exercise levels or alcohol consumption between statin users and non-users 
after adjusting for clinically important covariates. We found no evidence that people take 
statins to compensate a healthy lifestyle. Our results suggest that statin users in Australia may 
have a different lifestyle profile to statin users in the U.S. and Sweden. Longitudinal studies 
are needed to whether possible lifestyle modifications among statin users in Australia are 
sustained over time. 
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